These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 17874294

  • 1. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
    Bharat A, Benshoff N, Fleming TP, Dietz JR, Gillanders WE, Mohanakumar T.
    Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
    [Abstract] [Full Text] [Related]

  • 2. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR, Mohanakumar T.
    J Natl Cancer Inst; 2004 Sep 15; 96(18):1388-96. PubMed ID: 15367572
    [Abstract] [Full Text] [Related]

  • 3. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.
    Breast Cancer Res Treat; 2004 Nov 15; 88(1):29-41. PubMed ID: 15538043
    [Abstract] [Full Text] [Related]

  • 4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 5. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, Goedegebuure PS.
    Surgery; 2003 Jan 15; 133(1):74-80. PubMed ID: 12563241
    [Abstract] [Full Text] [Related]

  • 6. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.
    Clin Cancer Res; 2004 Oct 15; 10(20):6946-55. PubMed ID: 15501973
    [Abstract] [Full Text] [Related]

  • 7. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
    Hung CF, Calizo R, Tsai YC, He L, Wu TC.
    Vaccine; 2007 Jan 02; 25(1):127-35. PubMed ID: 16930783
    [Abstract] [Full Text] [Related]

  • 8. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer.
    Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE.
    Clin Cancer Res; 2014 Dec 01; 20(23):5964-75. PubMed ID: 25451106
    [Abstract] [Full Text] [Related]

  • 9. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer.
    Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, Mohanakumar T.
    Int J Cancer; 2002 Dec 10; 102(5):499-506. PubMed ID: 12432553
    [Abstract] [Full Text] [Related]

  • 10. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL, Schiffman K, Cheever MA, Disis ML.
    Clin Cancer Res; 2002 May 10; 8(5):1014-8. PubMed ID: 12006513
    [Abstract] [Full Text] [Related]

  • 11. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ.
    J Immunother; 2012 Apr 10; 35(3):235-44. PubMed ID: 22421941
    [Abstract] [Full Text] [Related]

  • 12. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.
    J Immunother; 2009 Apr 10; 32(6):613-21. PubMed ID: 19483648
    [Abstract] [Full Text] [Related]

  • 13. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N, Grenier AJ, Caty M, Charrier E, Duval A, Duval M, Champagne MA, Soudeyns H.
    J Immunol; 2010 Jul 15; 185(2):856-66. PubMed ID: 20543110
    [Abstract] [Full Text] [Related]

  • 14. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R, Paterson Y.
    Cancer Res; 2006 Aug 01; 66(15):7748-57. PubMed ID: 16885378
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.
    Cancer; 2006 Jun 01; 106(11):2309-17. PubMed ID: 16596621
    [Abstract] [Full Text] [Related]

  • 16. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.
    Viehl CT, Tanaka Y, Chen T, Frey DM, Tran A, Fleming TP, Eberlein TJ, Goedegebuure PS.
    Breast Cancer Res Treat; 2005 Jun 01; 91(3):271-8. PubMed ID: 15952060
    [Abstract] [Full Text] [Related]

  • 17. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.
    Breast Cancer Res Treat; 2006 Jul 01; 98(1):17-29. PubMed ID: 16758122
    [Abstract] [Full Text] [Related]

  • 18. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 19. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M.
    J Immunother; 2010 Apr 15; 33(3):250-61. PubMed ID: 20445345
    [Abstract] [Full Text] [Related]

  • 20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 15; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.